TCA
XBI icon

Transcend Capital Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Transcend Capital Advisors’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.48M Sell
27,225
-2,314
-8% -$289K 0.28% 64
2025
Q4 		$3.6M Sell
29,539
-4,529
-13% -$519K 0.28% 69
2025
Q3 		$3.41M Buy
34,068
+1
+0% +$90 0.24% 94
2025
Q2 		$2.83M Sell
34,067
-14,486
-30% -$1.16M 0.22% 106
2025
Q1 		$3.94M Sell
48,553
-797
-2% -$71.2K 0.28% 80
2024
Q4 		$4.44M Sell
49,350
-1,484
-3% -$144K 0.32% 72
2024
Q3 		$5.02M Sell
50,834
-3,275
-6% -$322K 0.34% 68
2024
Q2 		$5.02M Buy
54,109
+3,774
+7% +$338K 0.36% 63
2024
Q1 		$4.78M Buy
50,335
+2,131
+4% +$198K 0.38% 59
2023
Q4 		$4.3M Buy
48,204
+16,605
+53% +$1.23M 0.38% 60
2023
Q3 		$2.31M Buy
31,599
+18,820
+147% +$1.5M 0.22% 102
2023
Q2 		$1.06M Sell
12,779
-26
-0.2% -$2.17K 0.1% 203
2023
Q1 		$976K Sell
12,805
-897
-7% -$74.4K 0.1% 201
2022
Q4 		$1.14M Sell
13,702
-4,945
-27% -$400K 0.12% 185
2022
Q3 		$1.48M Buy
18,647
+122
+0.7% +$10.3K 0.16% 144
2022
Q2 		$1.38M Buy
18,525
+3,442
+23% +$258K 0.14% 160
2022
Q1 		$1.36M Sell
15,083
-124
-0.8% -$11.5K 0.12% 182
2021
Q4 		$1.7M Buy
15,207
+10,262
+208% +$1.24M 0.15% 157
2021
Q3 		$613K Buy
+4,945
New +$637K 0.05% 271
2021
Q2 		– Sell
-6,265
Closed -$851K – 436
2021
Q1 		$851K Buy
6,265
+33
+0.5% +$4.94K 0.1% 201
2020
Q4 		$877K Sell
6,232
-1,438
-19% -$184K 0.12% 183
2020
Q3 		$855K Buy
+7,670
New +$860K 0.16% 132

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Transcend Capital Advisors's XBI Position: Q1 2026 in Review

Transcend Capital Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 7.8% in Q1 2026, selling an estimated $289K and leaving 27,225 shares worth $3.48M. The position accounts for 0.28% of the portfolio, ranked #64.

Transcend Capital Advisors first reported a position in XBI in Q3 2020 and has held it in 22 quarters since. The position peaked at $5.02M in Q3 2024. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Transcend Capital Advisors held 27,225 shares of State Street SPDR S&P Biotech ETF worth $3.48M as of Q1 2026.
  • Transcend Capital Advisors sold 2,314 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $289K.
  • State Street SPDR S&P Biotech ETF made up 0.28% of Transcend Capital Advisors's portfolio in Q1 2026, its #64 holding.
  • Transcend Capital Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and has held it in 22 quarters since.
  • Transcend Capital Advisors's State Street SPDR S&P Biotech ETF position peaked at $5.02M in Q3 2024.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Transcend Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.